Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

This study is comparing how the MS medication ocrelizumab works differently in African American versus Caucasian patients with relapsing-remitting multiple sclerosis (MS). African Americans tend to have more aggressive MS but have been underrepresented in research, so this study aims to fill that gap. **You may be eligible if:** - You are between 18 and 60 years old - You identify as African American or Caucasian - You have relapsing-remitting MS (a type of MS where symptoms come and go) - Your neurologist has recommended ocrelizumab as your MS treatment - You have tried no more than one prior MS medication (or none at all) - Your MS disability score (EDSS) is between 0 and 6 **You may NOT be eligible if:** - You have been treated with certain other biologic or monoclonal antibody medications for MS (natalizumab, alemtuzumab, daclizumab) - You have failed two or more MS treatments - You have claustrophobia or allergy to contrast dye (which prevents MRI scans) - You are pregnant - You have a history of cancer, kidney failure, or liver insufficiency - You have had a relapse or used steroids in the past 30 days Talk to your doctor to see if this trial is right for you.